JP Morgan Private Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-2,500
Closed -$52K 2052
2021
Q4
$52K Sell
2,500
-322
-11% -$10.3K ﹤0.01% 1959
2021
Q3
$99K Buy
+2,822
New +$122K ﹤0.01% 1900

Other funds holding DFTX

JP Morgan Private Wealth Advisors's DFTX Position: Q1 2022 in Review

JP Morgan Private Wealth Advisors sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 2,500 shares — an estimated $52K sold.

JP Morgan Private Wealth Advisors first reported a position in DFTX in Q3 2021 and held it in 2 quarters. The position peaked at $99K in Q3 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • JP Morgan Private Wealth Advisors reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 2,500 Definium Therapeutics shares in Q1 2022, an estimated $52K.
  • JP Morgan Private Wealth Advisors first reported a position in Definium Therapeutics in Q3 2021 and held it in 2 quarters.
  • JP Morgan Private Wealth Advisors's Definium Therapeutics position peaked at $99K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.